Medivation stands firm as Sanofi threatens hostile takeover

6 May 2016
mergers-acquisitions-big

French pharma major Sanofi (Euronext: SAN) might have threatened to play hardball over its attempt to take over USA-based biotech Medivation (Nasdaq: MDVN), but the target company has hit back.

Sanofi’s latest letter to Medivation, reiterating its desire to go ahead with the $9.3 billion takeover and warning it would resort to a hostile takeover if necessary, has prompted a stern response.

Medivation, which has a leading oncology franchise, is seen as a hot property by big pharma, with US major Pfizer (NYSE: PFE) and Anglo-Swedish AstraZeneca (LSE: AZN) also reportedly interested.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology